J&J to buy targeted cancer therapy developer Ambrx for $2 billion
Reuters
Published Jan 08, 2024 07:51AM ET
Updated Jan 08, 2024 02:06PM ET
(Reuters) - Johnson & Johnson (NYSE:JNJ) said on Monday it had agreed to buy drug developer Ambrx Biopharma for $2 billion to gain access to drugs that belong to a class of targeted cancer therapies which have drawn interest from other drugmakers.
J&J will pay $28 per share of Ambrx, which represents a premium of about 105% to the stock's last close. Shares of the company surged to $27.24 in premarket trading.
Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as "guided missiles" to target cancer cells and minimize damage to healthy tissue.
The deal would help J&J add a promising therapy for cancer and move further into a hot space for drugmakers that has witnessed a rush of deals in recent months.
In November, AbbVie (NYSE:ABBV) said it would buy ADC-developer ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash. Other deals include Pfizer (NYSE:PFE)'s $43 billion deal for Seagen and Merck's MRK.N> announcement that it would pay Daiichi Sankyo $5.5 billion to jointly develop three ADCs.
Ambrx's lead treatment, named ARX517, is being tested in early-stage studies in patients with prostate cancer.
The company, which recently spun off its consumer health business, said it would use its expertise in prostate cancer therapies to speed up development of ARX517. J&J sells the prostate cancer drug Zytiga.
J&J has been focused on driving up sales in its medical devices and pharmaceuticals business since hiving off its consumer unit. U.S. sales of its blockbuster drug Stelara are expected to come under pressure in 2025.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.